Grand Prairie-based Neos Therapeutics has added a second attention deficit hyperactivity disorder medication as it seeks to bolster its position as a top provider in treatment of ADHD, according to a report in The Dallas Morning News.

Neos, which generated $10 million in revenue in a little more than a year, announced that Cotempla XR-ODTTM is on sale in select markets. It uses Neos’ proprietary extended-release disintegrating tablet technology, the Morning News said.

While not specifying which markets the drug is being sold in now, the company said that it will be available nationwide in October.

The tablets stimulate the patient’s central nervous system to control symptoms of impulsive behavior and inattention, the newspaper said. Food and Drug Administration approved the drug in June, according to Xconomy. 

NEOS’ FIRST ADHD DRUG CAME TO MARKET IN 2016

“With this approval, Neos will be the only company to have both a branded methylphenidate and a branded amphetamine product available in an extended-release orally disintegrating tablet dosage form,” Neos President and CEO Vipin Garg said in a press release.

Competitor drugs Ritalin and Adderall come as large pills that can be difficult to swallow, Xconomy reported, and Neos has reformulated the medication that is easier to take and releases over an extended period of time.

Neos’ first publicized drug called Adzenys XR-ODT, an amphetamine similar to Adderall, has generated more than $7.3 million in revenue so far in 2017, and more than $10.2 million since it came to market in May 2016, the Morning News reported. 

Adzenys is approved for use in children ages 6 to 17, although Chief Commercial Officer Tom McDonnell told investors that some physicians have extended the age range. Neos, in turn, has refocused some of its sales efforts on the adult market, the Morning News reported. 

More than 114,000 prescriptions have been filled for Adzenys since its launch in March, investors were told by company executives.

Neos announced in June that it had raised roughly $34.5 million in a public offering that will help it reach positive cash flow soon.

Dallas Innovates, every day